Itraconazole effectively controls active paracoccidioidomycosis but appears not to hinder lung fibrosis. Clinical records and chest radiographs from 47 itraconazole-treated patients with prolonged posttherapy follow-up (mean follow-up period, 5.6 years) were analyzed; the radiographs were interpreted following pneumoconiosis standards that consider the lungs as 6 fields and grade damage according to the number of fields involved. Infiltrative lesions were observed at diagnosis in 93.6% of the patients. Fibrosis was observed in 31.8% of the patients at diagnosis and had not cleared at the end of the observation period in any of these patients. Fibrosis also developed de novo in 11 patients (25%), so that by the end of the follow-up period it was seen in 53.2% of patients overall. Fibrosis correlated with severity of infiltrates at diagnosis: fibrosis was present in 83% of patients with very severe infiltration and in 12.5% of patients with minor infiltration. Among patients with severe infiltration, fibrosis was present in 30%; this increased (to 75%) when bullae were concomitantly present at diagnosis. Prompt initiation of treatment is necessary to avoid the development of fibrosis.
Itraconazole effectively controls active paracoccidioidomycosis but appears not to hinder lung fibrosis. Clinical records and chest radiographs from 47 itraconazole-treated patients with prolonged posttherapy follow-up (mean follow-up period, 5.6 years) were analyzed; the radiographs were interpreted following pneumoconiosis standards that consider the lungs as 6 fields and grade damage according to the number of fields involved. Infiltrative lesions were observed at diagnosis in 93.6% of the patients. Fibrosis was observed in 31.8% of the patients at diagnosis and had not cleared at the end of the observation period in any of these patients. Fibrosis also developed de novo in 11 patients (25%), so that by the end of the follow-up period it was seen in 53.2% of patients overall. Fibrosis correlated with severity of infiltrates at diagnosis: fibrosis was present in 83% of patients with very severe infiltration and in 12.5% of patients with minor infiltration. Among patients with severe infiltration, fibrosis was present in 30%; this increased (to 75%) when bullae were concomitantly present at diagnosis. Prompt initiation of treatment is necessary to avoid the development of fibrosis.
Paracoccidioidomycosis (PCM) is an important systemic mycosis in Latin America, especially in Brazil; in Colombia, the disease is also regularly diagnosed. The disorder is caused by the thermally dimorphic fungus Paracoccidioides brasiliensis, for which the habitat is as yet undiscovered. PCM is probably acquired by inhalation of infectious particles (conidia and mycelial fragments) produced by the mycelial form that reach the lungs, convert into the yeast form, and initiate primary infection. This process is usually asymptomatic but may result in overt disease over the course of years. When clinical manifestations become apparent, the disease may appear in an acute-subacute form (also called the "juvenile form") or a chronic, adult form. In both of these forms, the progression of the disease results in the involvement of other organs (e.g., lymph nodes, spleen, liver, adrenal glands, mucosae, and skin). The lungs are the main target and the site at which both active and residual lesions appear regularly [1, 2] .
Active pulmonary involvement and residual fibrotic lesions are observed in ∼80% and ∼60%, respectively, of patients with PCM. The fibrotic sequelae alter respiratory function and incapacitate the patient so that normal activities become a burden [3] [4] [5] . Thus, the lungs are a significant site of morbidity and mortality in patients with PCM [6] .
Despite the frequency with which pulmonary repercussions of this mycosis occur, clinical manifestations and auscultatory findings associated with the disease are minor. However, radiologic abnormalities are often extensive, which results in a dissociation between clinical and radiologic findings [3] [4] [5] 7] . The silent course of the disease results not only in late consultation but also in steady progression of lung damage, which affects the patient's health and hinders the determination of disease onset [1, 3, 7] . Physicians must be aware that the lungs are the target organs for P. brasiliensis and that, in areas where this organism is endemic, the lungs of patients with chronic, nonspecific constitutional symptoms should be examined radiologically. This inexpensive measure may reveal alterations that are suggestive of the mycosis, hopefully while the disease is in an early stage.
Treatment has profoundly changed the outcome for patients with this mycosis. The first therapeutic agents discovered to successfully treat the disease, sulfonamides, brought improvement in 160% of the patients when prolonged (3-5-year) courses of therapy were administered [8] . Amphotericin B also had a significant impact on more-severe cases [9] . Nonetheless, the most important advance was represented by azole derivatives; both ketoconazole and itraconazole facilitated ambulatory therapy, required shorter courses of treatment, and were associated with fewer secondary effects [9] [10] [11] . Itraconazole is a potent antimycotic against P. brasiliensis, both in vitro and in vivo. The administration of daily doses of 100-200 mg for 6 months results in clinical and mycological response in 95% of patients, and relapses occur in !5% [9, 11, 12] .
Despite the effectiveness of itraconazole therapy for treatment of active disease, the development of fibrotic sequelae does not appear to be modified by such treatment. In the present study, we examined the course of PCM in patients who received this triazole and determined the outcome of pulmonary abnormalities after an extended follow-up period.
PATIENTS AND METHODS
The records for 60 patients in whom PCM was diagnosed and who were treated with itraconazole at the Corporació n para Investigaciones Bioló gicas (Medellin, Colombia) during the period 1982-1990 were analyzed. Follow-up observations had been made for a period of 11 year after the end of treatment for all of these patients; however, 8 patients had to be excluded because of the presence of concomitant pulmonary tuberculosis or irregular posttherapy visits. In addition, 5 patients with the juvenile form of the mycosis were excluded, because the course of their disease (e.g., minor or no apparent lung involvement and the presence of symptoms that were not related to pulmonary disease) differed from that of the remaining patients. Consequently, the study group consisted of 47 patients who underwent radiologic examination of their lungs at diagnosis and through the end of the posttherapy observation period.
All patients were adult men (mean age, 49 years; range, 21-75 years). Thirty-nine patients (83.0%) had the chronic, multifocal, adult form of the mycosis, and the remaining 8 (17.0%) had the chronic, unifocal form. The principle associated factor was a history of smoking (present for 44 [93.6%] of the 47 patients).
The patients were treated with itraconazole, 100-200 mg/ day; the duration of treatment was determined by clinical presentation and response to treatment. Twenty-seven (69.2%) of the 39 patients with chronic, multifocal disease received treatment for a mean of 5.9 months (range, 3-6 months); the remaining 12 patients (30.8%) received a more prolonged course (mean, 10.4 months; range, 7-12 months). The 8 patients with the chronic, unifocal form received therapy for a mean of 5.5 months (range, 3-6 months). Two (4.3%) of the 47 patients had relapses during the observation period (!2 months after therapy cessation); they were treated again with itraconazole, and prompt control of the mycosis was achieved. Relapses were not considered to be additional (new) cases.
After itraconazole therapy was stopped, regular follow-up observations were made for a mean period of 5.6 years (range, 1-17 years). The distribution is as follows: for 25 patients, the duration of follow-up was 1-5 years; for 16 patients, 6-10 years; and for 6 patients, 11-17 years. All signs and symptoms (pulmonary or extrapulmonary) exhibited by the patients at diagnosis were recorded and compared with those at the end of the observation period.
Chest radiographs were initially read blindly (with no knowledge of the patient's name or the time at which the film was taken) by 2 members of our team (A.M.T. and M.L.O.), who then analyzed the results and classified the findings according to the extension of both infiltrative and fibrotic lesions with the lungs. The lung area was divided into 6 zones, according to the guidelines of the pneumoconiosis international classification of radiographs [13] . These guidelines trace horizontal lines along the superior, central, and inferior fields and vertical lines between the right and left fields; thus, fields comprise onethird and two-thirds of the vertical distance from the pulmonary apex to the dome of the diaphragm. Lung involvement was minor if only 1-2 fields were affected, severe if 3-4 fields were affected, and very severe if 5-6 fields were affected.
The classification and regression tree system proposed by Breiman et al. [14] was used to define factors predictive of the development of fibrosis in the patients studied. Two-way analysis of variance was used to determine differences among the groups.
RESULTS
The various signs and symptoms exhibited by the patients at the time of diagnosis and at the end of the posttherapy evaluation period are shown in table 1. Pulmonary alterations (cough, expectoration, and dyspnea) persisted for years in a substantial number of patients (138.3%). On the other hand, The alveolar component cleared after therapy in the 16 patients with mixed infiltrates; however, both components did not completely clear in all patients: in 5, the interstitial lesions remained. In the group of 29 patients with interstitial pathology, 14 had the same lesions at the end of follow-up as at the beginning. Thus, a total of 19 patients (43.2%) with infiltrative lesions had this abnormality at the end of the observation period (table 2) . No significant differences were found among the groups in the type of infiltrates or whether the lesions improved; however, a significant value ( ) was found when an intragroup P p .001 comparison was made for those patients in whom infiltrates had not resolved by the end of the study. Figures 1 and 2 illustrate the changes that occurred over time.
At diagnosis, the intensity of the infiltrates was classified as minor in 8 (18.1%) of the 44 patients with such lesions, severe in 18 patients (40.9%), and very severe in 18 patients (40.9%). At the end of treatment, 7 patients (15.9%) had no infiltrative lesions visible on radiographs; 12 (27.3%) had persistent infiltrates only, and 7 (15.9%) had both infiltrates and fibrosis (table 3) . In all, 19 patients (43.2%) had persistent infiltrative lesions. Resolution of the infiltrative lesions was also minor in patients with severe and patients with very severe infiltrates (11.1% for both groups). More than 33.4% of these patients had persistent infiltrates at the end of the observation period. The frequency of fibrosis increased with the severity of lung infiltration at diagnosis (table 3) ; thus, among the 18 patients who had shown infiltrative lesions in 5-6 pulmonary fields, 5 (27.8%) had fibrosis in addition to infiltrates and 10 (55.6%) had fibrosis at the end of the observation period ( ). P p .0001 Fibrotic lesions were found at diagnosis in 14 (31.8%) of the 44 patients with infiltrative lesions. The intensity of the fibrotic lesions was minor in 10 patients (22.7%), severe in 3 (6.8%), and very severe in 1 (2.3%). At the end of the study, fibrosis persisted in these 14 patients, and, furthermore, it appeared de novo in 11 patients, for a total of 25 patients (53.2%) with this residual sequela. The simultaneous presence of other residual lesions, such as bullae, was also noted, in 12 patients (27.3%). In addition, indirect signs of pulmonary hypertension, mainly abnormal thickening of the pulmonary hilar arteries, were recorded in 6 patients (13.6%). Twenty-six patients (59.1%) had bullae at the end of the observation period: 12 who had bullae at diagnosis, and 14 who developed it de novo. Signs of pulmonary hypertension persisted in all 6 patients, and 6 more patients developed pulmonary hypertension; in total, 12 patients (27.3%) had this finding at the end of the observation period. Fourteen (66.7%) of the 21 patients who had clinically manifested pulmonary signs (dyspnea and cor pulmonale) at the end of the observation period (table 1) had fibrosis visible on the final radiograph. However, of the 23 remaining patients with no clinically manifested pulmonary signs, fibrosis was present in 11 (47.8%); there was no statistically significant difference among the groups. Attempts were also made to determine the effect of smoking on the radiologic abnormalities detected in these 23 patients, but the attempts failed, because almost all (93.6%) of the patients smoked. In addition, no radiologic differences were found when the group was subdivided into those who had stopped smoking and those who had continued to do so.
In our patients, the intensity of the infiltrative component at time of diagnosis influenced the development of fibrosis, as shown by the classification and regression tree system [14] . Among patients in whom the initial infiltration was very severe (15 lung fields involved), the possibility of developing fibrosis over time was 83%. By contrast, this possibility was smaller (12.5%) for patients with minor infiltrative involvement (1-2 fields). In the group with a severe infiltrative component (13 lung areas), the possibility that fibrotic sequelae would be present at the end of the observation period was 30%; however, this figure increased to 75% when bullae were concomitantly present (table 4).
DISCUSSION
Once P. brasiliensis infectious propagules reach the lungs and convert into the yeast form in a susceptible host, dissemination throughout the pulmonary structures occurs, frequently producing extensive local damage that, later on, results in respiratory incapacity [3-5, 7, 15, 16] . Residual pulmonary involvement in patients with PCM is characterized by a variety of radiologic abnormalities distributed bilaterally, among which the following are important: infiltrative lesions of both the alveolar and the interstitial types, hypertrophied and calcified hilar and mediastinal lymph nodes, fibrosis, septum thickening, and pseudotumoral and fibronodular masses [3] [4] [5] 15] . The first 3 abnormalities were observed in our patients. High-resolution CT findings have emphasized that interstitial abnormalities are the predominant sequela in patients with PCM [16] .
It is known that, in an important number of patients, diagnosis of PCM is achieved late during the course of the infection, as a result, in part, of the silent nature of the primary pulmonary symptoms [7] . This circumstance explains why radiologic abnormalities that are consistent with old, established processes, such as fibrosis, are commonly found at diagnosis [4, 5, 15, 16] . This was seen in the present study, in which such alterations were observed in 31.8% of the patients at diagnosis, which is an alarming rate of residual lung damage. Steps should be taken to make physicians aware that, in the population considered at major risk (i.e., men who are employed in areas where PCM is endemic), obtaining radiologic images is mandatory, even in the absence of respiratory symptoms. It would also be desirable to work in cooperation with official campaigns established for the control of tuberculosis, so that pulmonary pathology compatible with this mycotic disorder can be detected. It has been shown that antifungal treatment effectively controls multiplication of P. brasiliensis, thus diminishing the infectious load [9] and allowing the expression of the patient's immune response [17, 18] . In the present study, which emphasized the pulmonary component of PCM, it was observed that, in the 16 patients (36.4%) who had mixed infiltrates, the alveolar component, probably the active lung lesion, disappeared completely. Of the 44 patients with infiltrative lesions, 25 (56.8%) had resolution of the infiltrations during the posttherapy observation period. Nonetheless, at the end of the observation period, only 7 (15.9%) were free of all lesions, and 18 (40.9%) had fibrotic scars, as described below.
At the end of the prolonged posttherapy observation of our patients, fibrosis persisted in those in whom it had been recorded at diagnosis and appeared de novo in some patients, so that 25 (53.2%) of the 47 patients had such sequelae at the end of the observation period. Bullae also persisted, and the frequency increased during the posttherapy follow-up period, until 59% of the patients had this sequela. Signs of pulmonary NOTE. Classification and regression trees are described in Breiman et al. [14] . n/N, no. of patients with fibrosis at any time/total no. of patients.
hypertension followed the same persistence-de novo course; 27.2% of patients had this sign at the end of the study.
The retrospective nature of the present study, the time (1982) at which the available records began to be analyzed, and the budgetary difficulties encountered when more-precise image studies, such as CT, were requested hindered further examination. Nonetheless, the data obtained indicate that, despite successful results of the use of itraconazole to treat active disease, residual lesions not only persist but increase over time, so that a sizeable proportion of patients have permanent impairment of life quality as a result of dyspnea and/or cor pulmonale.
The present study presented valuable information, demonstrating that the intensity of the infiltrative lesions present at the moment of diagnosis predicts the final outcome of residual lesions. The possibility that a patient will develop pulmonary fibrosis in spite of otherwise successful therapy was much greater when infiltration had been categorized as very severe at diagnosis (83%) than when infiltration was categorized as minor (12.5%). In addition, the simultaneous presence of severe infiltrative changes and of bullae during the first consultation contributed to the marked increase (to 75% of patients) in the frequency of pulmonary sequelae at the end of the observation period. Proper interpretation of lung images at diagnosis and emphasis on the significance of interstitial lesions that are already present may contribute to better patient surveillance. It would also seem desirable to have accessory therapies available that would help avoid or control fibrosis; unluckily, however, earlier experiences with corticosteroids and progesterone reported by clinicians in Argentina and Brazil (R. Negroni, personal communication) have proved unrewarding. Nonetheless, advances in our knowledge of the immune mechanisms involved in the genesis of fibrosis may allow immunomodulation of the patient's tissue response so that the development of sequelae may be prevented [19] .
The findings reported above emphasize that, even though treatment is essential to avoid progression of fungal disease and death in patients with PCM, efforts should also be made toward prompter diagnosis, so that undue lung damage attributable to the silent progress of the mycosis can be avoided. Despite the fact that such a course does not allow determination of the role of prompt treatment in avoiding residual lesions, studies in an experimental mouse model of pulmonary PCM have demonstrated that, if animals are treated with itraconazole shortly after challenge with the fungus, disease progression is halted and no fibrosis develops, in contrast with challenged but untreated animals [20] . Thus, if the mycosis were considered earlier in a physician's differential diagnosis, and if the available mycologic and image sources were used appropriately [1, 16] , an important decrease in the number of patients with incapacitating fibrosis might be obtained. The cost associated with advancement of molecular biology-based methods of diagnosis may be offset by the time saved in achieving diagnoses [21, 22] . Prospective studies that include CT image analysis are need to define the precise role of previous lung damage in the outcome of residual lesions in patients with PCM.
